Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vir Biotechnology Inc | VIR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 7.96 | 07:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.96 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 7.72 - 27.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 7.96 | USD |
Vir Biotechnology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.07B | 135.03M | - | 86.18M | -615.06M | -4.55 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Vir Biotechnology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VIR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.20 | 9.23 | 7.94 | 8.39 | 810,401 | -1.24 | -13.48% |
| 1 Month | 10.09 | 10.34 | 7.94 | 9.33 | 768,602 | -2.13 | -21.11% |
| 3 Months | 9.67 | 12.00 | 7.94 | 10.07 | 1,059,218 | -1.71 | -17.68% |
| 6 Months | 8.33 | 12.00 | 7.72 | 9.69 | 1,137,389 | -0.37 | -4.44% |
| 1 Year | 24.93 | 27.48 | 7.72 | 13.03 | 1,179,669 | -16.97 | -68.07% |
| 3 Years | 47.50 | 58.00 | 7.72 | 25.26 | 1,146,463 | -39.54 | -83.24% |
| 5 Years | 16.15 | 141.01 | 7.72 | 30.82 | 1,134,239 | -8.19 | -50.71% |
Vir Biotechnology Description
| Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. |
